Publicacións nas que colabora con Nuria María Ardaiz Iriarte (18)

2024

  1. Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4

  2. Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)

    Clinical science (London, England : 1979), Vol. 138, Núm. 20, pp. 1265-1284

2023

  1. Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure

    Molecular Therapy - Nucleic Acids, Vol. 33, pp. 599-616

2021

  1. Statins act as transient type i interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 7

2020

  1. Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice

    Frontiers in Pharmacology, Vol. 11

  2. Long-Term Liver Expression of an Apolipoprotein A-I Mimetic Peptide Attenuates Interferon-Alpha-Induced Inflammation and Promotes Antiviral Activity

    Frontiers in Immunology, Vol. 11

  3. Scavenger Receptor Class B Type I is Required for 25-Hydroxycholecalciferol Cellular Uptake and Signaling in Myeloid Cells

    Molecular Nutrition and Food Research, Vol. 64, Núm. 15

2019

  1. Treatment of experimental autoimmune encephalomyelitis by sustained delivery of low-dose IFN-a

    Journal of Immunology, Vol. 203, Núm. 3, pp. 696-704

2017

  1. Antitumor effect of an adeno-associated virus expressing apolipoprotein A-1 fused to interferon alpha in an interferon alpha-resistant murine tumor model

    Oncotarget, Vol. 8, Núm. 3, pp. 5247-5255

2016

  1. Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function

    OncoImmunology, Vol. 5, Núm. 8

2015

  1. Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I

    Journal of Hepatology, Vol. 63, Núm. 2, pp. 329-336

  2. Overexpression of apolipoprotein A-I fused to an anti-transforming growth factor beta peptide modulates the tumorigenicity and immunogenicity of mouse colon cancer cells

    Cancer Immunology, Immunotherapy, Vol. 64, Núm. 6, pp. 717-725

2014

  1. Harnessing high density lipoproteins to block transforming growth factor beta and to inhibit the growth of liver tumor metastases

    PLoS ONE, Vol. 9, Núm. 5

2012

  1. A Semliki Forest virus vector engineered to express IFNα induces efficient elimination of established tumors

    Gene Therapy, Vol. 19, Núm. 3, pp. 271-278

  2. Kinetic and dynamic computational model-based characterization of new proteins in mice: Application to interferon alpha linked to apolipoprotein A-I

    PLoS ONE, Vol. 7, Núm. 7

  3. The fusion protein of IFN-α and apolipoprotein A-I crosses the blood-brain barrier by a saturable transport mechanism

    Journal of Immunology, Vol. 188, Núm. 8, pp. 3988-3992

2011

  1. Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties

    Hepatology, Vol. 53, Núm. 6, pp. 1864-1873

  2. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells

    Journal of Immunology, Vol. 186, Núm. 2, pp. 807-815